7/14 Early treatment study
et al., Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint)
A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Small 116 patient RCT comparing Ivermectin-Doxycycline and HCQ+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for Ivermectin-Doxycycline vs. 6.99 days for HCQ+AZ. Given the long half-life of HCQ and the lack of a loading dose, it may take several days for HCQ to reach therapeutic levels. 10% of HCQ+AZ patients were lost to followup (2x Ivermectin-Doxycycline). There is no comparison with a control group.
Chowdhury et al., 7/14/2020, Double Blind Randomized Controlled Trial, preprint, 6 authors.
